Janssen Biotech Adds Tesaro’s Niraparib to its Prostate Cancer Portfolio in a US$500 M Deal
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 5 (Table of Contents)
Published: 25 May-2016
DOI: 10.3833/pdr.v2016.i5.2160 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
To complement its prostate cancer franchise, which is currently lead by Zytiga® (abiraterone acetate), Janssen Biotech, the wholly owned subsidiary of Johnson & Johnson,has entered into a collaboration and license agreement with US-based Tesaro for the global (excluding Japan) development and future marketing rights of the PARP inhibitor, niraparib, for use in prostate cancer in a deal worth up to US$500 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS